---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-046043"
form_type: "8-K"
ticker: "EVFM"
cik: "0001618835"
company_name: "Evofem Biosciences, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:29:20.869213+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Evofem Biosciences Q3 2024 operating loss narrows to $2.4M; acquires SOLOSEC, licenses Phexxi in Middle East

## Summary
- Net product sales $4.5M in Q3 2024, down 12% YoY from $5.1M; operating loss improved 31% to $2.4M.
- Net loss attributable to common stockholders $2.4M ($0.02/sh) vs net income $66.0M ($15.34/sh) in Q3 2023 due to prior-year debt extinguishment gain.
- Acquired global rights to SOLOSEC (secnidazole) 2g oral granules, FDA-approved for BV and trichomoniasis, relaunched as single-dose treatment.
- Licensed Phexxi commercial rights in Middle East to Pharma 1 Drug Store; UAE regulatory submission on track by year-end 2024.
- Aditxt invested $5.0M since May 2024, including $1.3M in Q3 and $2.7M in October 2024, under amended merger agreement.

## SEC filing metadata
- accession: 0001493152-24-046043
- form_type: 8-K
- ticker: EVFM
- cik: 0001618835
- company_name: Evofem Biosciences, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1618835/000149315224046043/0001493152-24-046043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1618835/000149315224046043/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-046043
- JSON: https://secwatch.observer/filing/0001493152-24-046043.json
- Plain text: https://secwatch.observer/filing/0001493152-24-046043.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.